Glaukos Co. (NYSE:GKOS) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its holdings in shares of Glaukos Co. (NYSE:GKOS) by 421.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,211 shares of the medical instruments supplier’s stock after purchasing an additional 64,031 shares during the period. Victory Capital Management Inc. owned approximately 0.14% of Glaukos worth $10,320,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Values First Advisors Inc. acquired a new stake in Glaukos during the 3rd quarter worth about $25,000. GAMMA Investing LLC lifted its position in shares of Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after acquiring an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in Glaukos in the 2nd quarter worth approximately $187,000. Brighton Jones LLC purchased a new position in Glaukos during the 2nd quarter worth approximately $208,000. Finally, Procyon Advisors LLC purchased a new position in Glaukos during the 3rd quarter worth approximately $210,000. 99.04% of the stock is currently owned by institutional investors.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. This represents a 8.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GKOS. Wells Fargo & Company lifted their price target on Glaukos from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Stifel Nicolaus lifted their target price on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. BTIG Research increased their price target on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Finally, Piper Sandler set a $140.00 target price on shares of Glaukos in a research report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.55.

Glaukos Price Performance

NYSE GKOS opened at $141.44 on Thursday. Glaukos Co. has a fifty-two week low of $59.22 and a fifty-two week high of $145.84. The stock’s 50-day moving average is $131.75 and its two-hundred day moving average is $123.18. The firm has a market cap of $7.80 billion, a P/E ratio of -46.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. During the same quarter in the prior year, the firm posted ($0.50) EPS. The firm’s revenue for the quarter was up 23.9% on a year-over-year basis. On average, analysts anticipate that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.